DDInter1718 DDInter1652
Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Sufentanil {u} (Compound) resembles {v} (Compound) Anileridine
Sufentanil {u} (Compound) binds {v} (Gene) OPRM1
Sufentanil {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Sufentanil {u} (Compound) causes {v} (Side Effect) Vomiting
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desmopressin
Sufentanil {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Sufentanil {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Sufentanil (Compound) resembles Anileridine (Compound)
Sufentanil (Compound) binds OPRM1 (Gene)
Sufentanil (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Sufentanil (Compound) causes Vomiting (Side Effect)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin
Sufentanil may lead to a major life threatening interaction when taken with Dexfenfluramine
Sufentanil may lead to a major life threatening interaction when taken with Naltrexone